| Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ... Clinical cancer research 18 (22), 6260-6270, 2012 | 258 | 2012 |
| Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth E Leone, E Morelli, MT Di Martino, N Amodio, U Foresta, A Gullà, M Rossi, ... Clinical Cancer Research 19 (8), 2096-2106, 2013 | 230 | 2013 |
| Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity N Amodio, MA Stamato, G Juli, E Morelli, M Fulciniti, M Manzoni, E Taiana, ... Leukemia 32 (9), 1948-1957, 2018 | 216 | 2018 |
| Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma N Amodio, MA Stamato, AM Gullà, E Morelli, E Romeo, L Raimondi, ... Molecular cancer therapeutics 15 (6), 1364-1375, 2016 | 122 | 2016 |
| Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo E Morelli, E Leone, ME Cantafio, MT Di Martino, N Amodio, L Biamonte, ... Leukemia 29 (11), 2173-2183, 2015 | 121 | 2015 |
| A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells A Gulla, MT Di Martino, ME Gallo Cantafio, E Morelli, N Amodio, C Botta, ... Clinical cancer research 22 (5), 1222-1233, 2016 | 116 | 2016 |
| Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts MR Pitari, M Rossi, N Amodio, C Botta, E Morelli, C Federico, A Gullà, ... Oncotarget 6 (29), 27343, 2015 | 112 | 2015 |
| In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells MT Di Martino, A Gullà, ME Gallo Cantafio, E Altomare, N Amodio, ... PloS one 9 (2), e89659, 2014 | 102 | 2014 |
| Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma A Gullà, T Hideshima, G Bianchi, M Fulciniti, M Kemal Samur, J Qi, YT Tai, ... Leukemia 32 (4), 996-1002, 2018 | 95 | 2018 |
| Bortezomib induces anti–multiple myeloma immune response mediated by cGAS/STING pathway activation A Gulla, E Morelli, MK Samur, C Botta, T Hideshima, G Bianchi, M Fulciniti, ... Blood cancer discovery 2 (5), 468-483, 2021 | 89 | 2021 |
| Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells G Nassa, A Salvati, R Tarallo, V Gigantino, E Alexandrova, D Memoli, ... Science advances 5 (2), eaav5590, 2019 | 78 | 2019 |
| The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment F Fan, MH Bashari, E Morelli, G Tonon, S Malvestiti, S Vallet, M Jarahian, ... Leukemia 31 (7), 1570-1581, 2017 | 75 | 2017 |
| Molecular targets for the treatment of multiple myeloma M Rossi, M Teresa Di Martino, E Morelli, M Leotta, A Rizzo, A Grimaldi, ... Current cancer drug targets 12 (7), 757-767, 2012 | 73 | 2012 |
| Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling M Ho, T Chen, J Liu, P Dowling, T Hideshima, L Zhang, E Morelli, ... Leukemia 34 (1), 196-209, 2020 | 62 | 2020 |
| Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 E Morelli, L Biamonte, C Federico, N Amodio, MT Di Martino, ... Blood, The Journal of the American Society of Hematology 132 (10), 1050-1063, 2018 | 61 | 2018 |
| MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells C Botta, M Cuce, MR Pitari, D Caracciolo, A Gulla, E Morelli, C Riillo, ... Leukemia 32 (4), 1003-1015, 2018 | 61 | 2018 |
| MicroRNAs: novel crossroads between myeloma cells and the bone marrow microenvironment L Raimondi, A De Luca, E Morelli, G Giavaresi, P Tagliaferri, P Tassone, ... BioMed Research International 2016 (1), 6504593, 2016 | 60 | 2016 |
| miR-22 suppresses DNA ligase III addiction in multiple myeloma D Caracciolo, MT Di Martino, N Amodio, E Morelli, M Montesano, C Botta, ... Leukemia 33 (2), 487-498, 2019 | 53 | 2019 |
| Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma D Caracciolo, F Scionti, G Juli, E Altomare, G Golino, K Todoerti, ... Haematologica 106 (1), 185, 2021 | 39 | 2021 |
| The non-coding RNA landscape of plasma cell dyscrasias E Morelli, A Gullà, R Rocca, C Federico, L Raimondi, S Malvestiti, ... Cancers 12 (2), 320, 2020 | 30 | 2020 |
Pierfrancesco TassoneProfessor of Medical Oncology, Magna Graecia University, Catanzaro, Italy在 unicz.it 的电子邮件经过验证
